TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06505772
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) for intravenous infusion is supplied in pre-filled syringes of 20 ml, 50 ml, and 100 ml. To maintain blinding in this study, NS is handled identically to the study drug, dexmedetomidine. A physician not involved in the study prepares all injections, randomly assigning either NS or dexmedetomidine using a sealed envelope technique. Prepared syringes are then placed in identical, unmarked infusion pumps.~Infusion Protocol:~Anesthesiologists, blinded to the infusion contents, administer the solutions according to the protocol:~For example,Initial Bolus: 4 ml infused over 10 minutes, Maintenance Infusion: Continued at a rate of 1.6 ml/kg/hour, adjusted to the individual patient's weight.~This process ensures both patient and anesthesiologist remain blinded to the treatment arm, minimizing potential bias throughout the study.
Study: NCT06294743
Drug: Acetaminophen 500Mg Tab
Normalized name: ACETAMINOPHEN 500MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen 500mg tab stat, followed by Q6h if needed.
Study: NCT05488821
Drug: QLH11906
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLH11906 only
Study: NCT06021860
Drug: Spironolactone Oral Suspension
Normalized name: Spironolactone Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone will be dosed on a mg/kg basis, with actual weight on Day 1 (pre-dose) determining the spironolactone suspension volume administered. Therefore, for a given patient, the dose administered on Day 1, based on the weight measured on Day 1, will be administered throughout their participation in the study.~Spironolactone will be administered as a single dose in the single-dose periods (Group 4, Parts 1 and 2), and as QD dosing in the multiple-dose periods (Groups 1 to 4, Parts 1 and 2).~The low and high doses to be administered during Part 2 of the study will be determined by the Safety Review Committee following their review of Part 1 data.
Study: NCT05918198
Drug: Ven+CAG
Normalized name: Apis mellifera ven protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg on the first day, and then gradually increase to the target dose of 400 mg (100 mg d1, 200 mg d2, 400 mg d3) within 3 days; After that, the drug continued to be administered until the 14th day, 400 mg/day. When combined with CYP3A or P-gp inhibitors (mainly voriconazole in this study), adjust the venetoclax dose to 100 mg/day.~Ara-C 10mg/m2, ih, q12h × 14d； Acla 20mg/d × 4d； G-CSF 5ug/kg × 14d (WBC \> 30 × 10\^9/L pause)
Study: NCT06415305
Drug: Winlevi (clascoterone) 1% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed twice daily (BID)
Study: NCT06574191
Drug: Topical Diclofenac gel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical NSAID
Study: NCT05884866
Drug: Balcinrenone 50mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arms
Study: NCT05884866
Drug: Balcinrenone 100mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arms
Study: NCT05884866
Drug: Balcinrenone 50mg matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arms
Study: NCT05884866
Drug: Balcinrenone 100mg matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arms
Study: NCT05105035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be prescribed placebo every 12 hours for Days 1-14.
Study: NCT05311215
Drug: SL-1002
Normalized name: citric acid 1002 MG
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SL-1002 injectable solution
Study: NCT05311215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo injectable solution
Study: NCT05773053
Drug: NT 201
Normalized name: Fluarix Quadrivalent 2013-2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.
Study: NCT05773053
Drug: NT 201 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT 201 Matching-placebo.
Study: NCT04718844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride for s.c. injection
Study: NCT04752644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBS (Placebo) as intramuscular injections (0.5ml)
Study: NCT04727580
Drug: HSK7653 10mg Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12
Study: NCT04727580
Drug: HSK7653 25mg Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
Study: NCT04727580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
Study: NCT05641623
Drug: OSU6162
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSU6162
Study: NCT05641623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04578834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to LNP023 200mg b.i.d
Study: NCT04578834
Drug: LNP023
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNP023 200mg b.i.d
Study: NCT05049902
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use according to the drug combination options selected by each center.
Study: NCT05049902
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use according to the drug combination options selected by each center.
Study: NCT05527288
Drug: Drug: [18F]florbetaben
Approvals — FDA: no, EMA: no, PMDA: no
Description: All eligible patients will receive a single administration of the imaging agent \[18F\]florbetaben at a radioactive dose of 300 MBq.
Study: NCT06092047
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2/day×3 days
Study: NCT04422275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.
Study: NCT05787600
Drug: Perhyal rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid Subjects will then be given the test intervention, Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
Study: NCT05787600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
Study: NCT06221657
Drug: Virreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet once a day, oral administration
Study: NCT05668390
Drug: STALORAL® Birch 300 IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 treatment periods will consist of 2 steps: an escalation phase, where the treatment dose will gradually increase, followed by a maintenance phase.
Study: NCT04810689
Drug: Xuanfei Baidu Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuanfei Baidu granules is a prescription of 13 herbal medicinals made into dissolvable granules for oral intake
Study: NCT05581199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo SC
Study: NCT04421079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparable placebo supplement which is manufactured according to GMP and will contain inert substances.
Study: NCT05226351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single administration of placebo oral (oily solution)
Study: NCT04838808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily for 90-days
Study: NCT05962151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT06580587
Drug: MK-8527
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04274426
Drug: Pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD will be administered by intravenous route
Study: NCT05511363
Drug: KarXT
Approvals — FDA: no, EMA: no, PMDA: no
Description: KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID
Study: NCT05511363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsules
Study: NCT05060913
Drug: Benzocaine Gel
Normalized name: Benzocaine Gel
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Effect of 20% Benzocaine gel on pricking pain measured on VAS scale.
Study: NCT05375968
Drug: Compare change is SVC and SMA flow due to saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
Study: NCT05246982
Drug: HLX07+HLX10+oxaliplatin+capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HLX07 1500mg+HLX10 300mg+oxaliplatin 130mg/m2+capecitabine 1000mg/m2 q3w
Study: NCT05964335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05702853
Drug: Cyclophosphamide injection
Normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3
Study: NCT05117476
Drug: CLN-619
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-MICA/MICB monoclonal antibody
Study: NCT05772351
Drug: micronized flavonoid fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery.~Under spinal anesthesia appropriate surgical intervention was performed. After the surgery, the patient was given a questionnaire and a scale for assessing pain at rest and during defecation within the first 2 weeks after surgery. During the hospital stay, the nurse filled out a section on the drugs used; after discharge, the patient filled out this section for 7 days after the surgery. After 30 days, the side effects section was filled out, and the quality of life was assessed on days 7 and 30. Also, the patients indicated in a separate column on which day after the surgery they were able to return to normal living or go to work.
Study: NCT04649892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
Study: NCT06063291
Drug: ID110521156
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
Study: NCT06238479
Drug: LY4101174
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT06063291
Drug: Placebo of ID110521156
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
Study: NCT05790161
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg/kg, once before night 6 and once before the scan (either on week 1 or 2, alternating with placebo)
Study: NCT06693336
Drug: SMS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time administration
Study: NCT05717166
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-specified based on the standard of care approach for that patient.
Study: NCT05717166
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-specified based on the standard of care approach for that patient.
Study: NCT05717166
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-specified based on the standard of care approach for that patient.
Study: NCT05717166
Drug: Targeted Systemic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-specified based on the standard of care approach for that patient.
Study: NCT04769206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill a day for 4 weeks, 2 pills a day for 8 weeks
Study: NCT06422403
Drug: Extended Dosing Interval - B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab + Atezolizumab 1200mg 6 weekly (up to 2 years)
Study: NCT06422403
Drug: Standard of Care - A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 360mg 3 weekly (up to 2 years) + XELOX Nivolumab 240mg 2 weekly (up to 2 years) + FOLFOX
Study: NCT06422403
Drug: Standard of Care - B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab + Atezolizumab 1200mg 3 weekly (up to 2 years)
Study: NCT06422403
Drug: Standard of Care - C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200mg 3 weekly (up to 2 years)
Study: NCT06567717
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc has not previously been investigated in the treatment of IPF.
Study: NCT05770674
Drug: 1 Month vs. 12 Months DAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation~1. 1 Month following PCI, followed by clopidogrel monotherapy~2. 12 Months following PCI
Study: NCT05503901
Drug: STN1012600 ophthalmic solution 0.002%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
Study: NCT06311656
Drug: LY4100511 (DC-853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally fasted
Study: NCT06311656
Drug: LY4100511 (DC-853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally fasted.
Study: NCT06311656
Drug: LY4100511 (DC-853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally fed and fasted.
Study: NCT06311656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04951921
Drug: Hyperpolarized 13C Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedure: Magnetic Resonance Imaging Undergo 1H-MRI of DWI/MRF/CEST for tumor cite following by 13C DNP-MRI for spleen for 3-5 minutes after hyperpolarized 13C pyruvate injection
Study: NCT05981365
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug drug interaction
Study: NCT05981365
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug drug interaction
Study: NCT05448820
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline
Study: NCT04401709
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 \~ 14 days for 3 weeks
Study: NCT04869501
Drug: TJ004309
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody to CD73
Study: NCT06622824
Drug: KX-826 0.5% BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
Study: NCT06622824
Drug: KX-826 1.0% BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
Study: NCT06622824
Drug: Vehicle (Placebo) applied BID
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo applied topically to scalp twice daily for 24 weeks
Study: NCT05539989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL (sodium chloride for injection 0.9%)
Study: NCT06109402
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04819932
Drug: DWJ1451
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202008 DWC202009
Study: NCT06516133
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy: If given, platinum-based.
Study: NCT06516133
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy: If given, platinum-based
Study: NCT05171920
Drug: Auxora
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive 2.0 mg/kg (1.25 mL/kg) of Auxora at 0 hour and 1.6 mg/kg (1 mL/kg) at both 24 hours and 48 hours from the Start of the First Infusion of Auxora (SFIA) at 0 hour over 4 hours. Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive extended treatment with Auxora 1.6 mg/kg (1 mL/kg) at 72, 96, and 120 hours from the SFIA
Study: NCT05171920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive 1 mL/kg of Placebo at 72, 96, and 120 hours from the SFIA.
Study: NCT06568237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally
Study: NCT05900206
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active comparator. IV infusion.
Study: NCT05458011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Study: NCT05274750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as normal saline using a pre-filled syringe.
Study: NCT06464367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: synthetic THC 2.5 mg (oral)
Study: NCT05874167
Drug: DW6013
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: DW6013 Single oral administration of DW6013 after an overnight fast~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin after an overnight fast
Study: NCT05153590
Drug: Saxenda®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups.
Study: NCT05662670
Drug: WJ13404 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily.~(It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor).~Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D.~Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied.
Study: NCT05321420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06482034
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: zinc sulfate capsules
Study: NCT05387499
Drug: NP-011 (Single Ascending Dose Phase)
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive assigned single dose of NP-011 after a minimum 8 hour fast on Day 1
Study: NCT05387499
Drug: NP-011 (Multiple Ascending Dose Phase)
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive assigned dose of NP-011 after a minimum 8 hour fast once daily for 7 days
Study: NCT03090048
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin monohydrate
Study: NCT05921370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery.
Study: NCT06046222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT05065957
Drug: mFOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion on Day 1 for 14-day cycle
Study: NCT06449274
Drug: Guideline-directed medical treatment
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: All individuals will receive guideline-directed medical treatment.
Study: NCT04743570
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug/placebo is given for the first 5 days of admission.